Stock CTLT CATALENT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Catalent, Inc.

Equities

CTLT

US1488061029

Real-time Estimate Cboe BZX
Other stock markets
 10:16:49 2024-04-29 EDT 		5-day change 1st Jan Change
56.46 USD +0.97% Intraday chart for Catalent, Inc. +0.11% +24.88%
04-12 Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48 MT
04-08 Sector Update: Health Care Stocks Decline Late Afternoon MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • With an enterprise value anticipated at 3.38 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CATALENT, INC. Stock Catalent, Inc.
+24.88% 10.12B
C
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.02% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.20% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.44% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.57% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.64% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.32% 231B
B+
NOVARTIS AG Stock Novartis AG
+5.18% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.00% 195B
A+
AMGEN INC. Stock Amgen Inc.
-4.91% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CTLT Stock
  4. Ratings Catalent, Inc.